Русский
Combined approaches to treating external genital warts in women
Gasanova G.F., Apolikhina I.A., Dodova E.G., Gorbunova E.A.
1Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; 2I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia;
Subjects and methods. A bicenter randomized open-label controlled comparative study was conducted. It included 93 patients with PC of the external genitalia, who were divided into 3 groups after CO2 laser destruction of PC. Group 1 (n = 31) received combined therapy with interferon-α (IFN-α) as rectal suppositories for 10 days in combination with oral indole-3-carbinol (I3C) tablets for 6 months. For the prevention of recurrent PC, Group 2 (n = 31) had only standard immunomodulatory therapy with IFN-α as rectal suppositories. A control group (n = 31) did not use pharmacotherapy. The investigators carried out photo fixation of PC and qualitative tests for human papillomavirus (HPV) by a PCR assay.
Results. Six months after destruction, the PC recurrence rates were 6.5% in Group 1, 25.8% in Group 2, and 32.3% in the control group (p = 0.010). None of the groups were found to have recurrent PC at 12 months following treatment initiation. According to the data of HPV diagnosis (a common qualitative test), after the therapy within a 12-month follow-up, the viral elimination rates were 85.7% in Group 1, 66.66% in Group 2, and 54.54% in the control group. After 12 months of treatment initiation, the HPV types 6 and 11 elimination rates were 87.5% in Group 1, 85.7% in Group 2, and 75.0% in the control group. In these groups, HPV types 31 and 33 were eliminated in 83.3, 80, and 100% of cases, respectively. The high-risk HPV types 16 and 18 elimination rates were 100, 83.3, and 0%, respectively.
Conclusion. There was a statistically significant reduction in the rate of recurrent PC of the external female genitalia, as well as HPV elimination and reduced reinfection especially with high-risk HPV types 16 and 18 during combined therapy with I3C and IFN-α. A combination of I3C and IFN-α showed a higher efficacy than the conventional use of IFN-α only.
Literature
1. Prilepskаya V.N., ed. [Diseases of the cervix (clinical lectures)]. Moscow: Media Sphera, 1997. 882 р. (In Russ.). 2. Lopuhov P.D., Briko N.I., Tsapkova N.N., Khaldin A.A., Zhukova O.V., Isaeva D.R., Lupashko O.V. [Malignant and benign neoplasms caused by human papillomavirus in the Russian Federation and in Moscow]. Èpidemiologiá i infekcionnye bolezni. Аktual’nye voprosy 2016; (4): 52–6. (In Russ.). 3. Kubanova A.A., Kubanov A.A., Melehina L.E., Bogdanova E.V. Dermatovenereology in the Russian Federation. The end of 2014. Success, achievement. The main ways of development]. Vestnik Dermatologii i Venerologii 2015; (4): 13–26. (In Russ.). 4. Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013; 13: 39. 5. Park I.U., Introcaso C., Dunne E.F.. Human Papillomavirus and Genital Warts: а Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin. Infect. Dis. 2015; 61(Suppl. 8): 849–55. 6. Bosch F.X., Broker T.R., Forman D., Moscicki A.-B., Gillison M.L., Doorbar J., Stern P.L. Comprehensive Control of Human Papillomavirus infections and Related Diseases. Vaccine 2013; 31(Suppl.7): 3–31. 7. Kulakov V.I., ed. [National guiedlines of gyneacology. Moscow: GEOTAR-Media, 2007: 482–3. (In Russ.). 8. Systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009; 9: 119. 9. [Guidelines for treatment of sexually transmitted diseases. Per. from English. Association to combat sexually transmitted diseases – SANAM]. Moscow: Venera-pres, 1998. 135 p. (In Russ.). 10. [Russian society of dermatovenerologists and cosmetologists. Federal clinical guiedlines. Dermatovenerology. Skin diseases and sexually transmitted infections]. Moscow: DELOVOJ ЕХPRESS Publ., 2016; 635–45 (In Russ.). 11. Apolihina I. A. [Optimization of therapeutic and diagnostic interventions in human papillomavirus infection]. Сand. Med. Diss. Moscow, 1999. (In Russ.). 12. Auborn K.J., Woodworth C., DiPaolo J.A., Bradlow H.L. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int. J. Cancer 1991; 49(6): 867. 13. Lawrence J.A., Malpas P.B., Sigman C.C., Kelloff G.J. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. Cell Biochem. 2000; 34(Suppl.1): 103–14. 14. Stern P.L., van der Burg S.H., Hampson I.N., Broker T.R., Fiander A., Lacey C.J., Kitchener H.C., Einstein M.H. Therapy of human papillomavirus-related disease. Vaccine 2012; 30(Suppl.5): 71–82. 15. Isakov V.A., Ermolenko D.K., Ermolenko E.I. [Herpesvirus and papillomavirus infection]. In: Akovbyan V.A., Prohorenkov V.I., Sokolovskiy E.V., eds. [Sexually transmitted infections]. Moscow: Media Sfera; 2007; 448– 513. (In Russ.). 16. Prilepskaya V.N., Dovlethanova Ye.R. [Peculiarities of diagnostics, clinical picture and treatment of diseases associated with HPV infection]. Ginekologiya 2013; 15(5): 7–12. (In Russ.). 17. Kiselev V.I., Dmitriev G.A., Kubanova A.A. [The relationship of viral sexually transmitted infections, and cancer of the urogenital tract]. Vestnik Dermatologii i Venerologii 2000; (6): 20–3. (In Russ.). 18. Shperling N.V., Vengerovskij A.I., Persidskaja O.A., Shperling I.A. [Experience with the use of Indinol Forte in recurrent human papillomavirus infection of the genitals]. Klinitceskaya Dermatologiya i Venerologiya 2009; (2): 32–6. (In Russ.). 19. Strizhakov A.N., Davydov A.I. [Gynecology. A course of lectures]. Moscow: GЕOTAR-Media; 2009: 91–7. (In Russ.). 20. Dolgushina V.V., Ahmatova A.N., Berenda M.A. [The effectiveness of isoprinosine in the treatment of chronic cervicitis associated with human papillomavirus infection]. Farmateka 2009; (14): 73–6. (In Russ.).
About the Autors
For correspondence:
Gulnar F. Gasanova, Postgraduate Student, Academician V.I. Kulakov Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Address: 4, Academician Oparin St., Moscow117997, Russia
E-mail: g_gasanova@oparina4.ru
Information about the autors:
Prof. Inna A. Apolikhina, MD, Head, Department of Aesthetic Gynecology and Rehabilitation, Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; Prof., Department of Obstetrics, Gynecology, and Reproductology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Moscow, Russia; e-mail: i_apolikhina@oparina4.ru;
Elena G. Dodova, Postgraduate Student, Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; e-mail: adeli575@mail.ru
Elena A. Gorbunova, Obstetrician-Gynecologist, Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia; e-mail: el_gorbunova@oparina4.ru
Similar Articles
